Breakdown | ||||
TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
4.13M | 3.26M | 4.55M | 448.82K | 0.00 | Gross Profit |
-17.18M | -8.13M | -8.87M | -10.06M | -2.52K | EBIT |
-31.79M | -29.79M | -32.06M | -39.18M | -1.37M | EBITDA |
-40.66M | -39.48M | -30.78M | -39.45M | -1.36M | Net Income Common Stockholders |
-43.71M | -45.07M | -36.41M | -39.36M | -1.37M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
8.19M | 7.98M | 10.99M | 5.57M | 536.08K | Total Assets |
22.13M | 22.13M | 22.73M | 14.62M | 1.85M | Total Debt |
31.41M | 31.41M | 18.96M | 2.31M | 824.56K | Net Debt |
23.22M | 23.43M | 7.97M | -3.26M | 288.48K | Total Liabilities |
41.76M | 41.76M | 22.09M | 8.32M | 3.00M | Stockholders Equity |
-19.63M | -19.63M | 635.01K | 6.30M | -1.14M |
Cash Flow | Free Cash Flow | |||
-25.45M | -30.52M | -34.45M | -25.00M | -1.40M | Operating Cash Flow |
-25.04M | -29.57M | -33.65M | -24.16M | -1.16M | Investing Cash Flow |
-329.97K | -860.72K | -799.41K | -838.03K | -249.04K | Financing Cash Flow |
28.31M | 27.08M | 40.41M | 30.03M | 1.94M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
72 Outperform | $2.23B | 15.60 | 10.42% | 4.92% | -1.15% | 121.43% | |
68 Neutral | $3.13B | 7.30 | 14.19% | 2.77% | -11.13% | -31.78% | |
64 Neutral | $288.81M | ― | -1.53% | ― | -45.70% | -115.77% | |
62 Neutral | $4.10B | 20.45 | 5.13% | 2.54% | -8.45% | -25.41% | |
59 Neutral | $12.24B | 11.04 | -1.00% | 3.78% | 1.30% | -19.54% | |
53 Neutral | $2.31B | 21.21 | 8.18% | 6.38% | -19.69% | -77.72% | |
28 Underperform | $3.26M | ― | -864.11% | ― | 23.80% | 99.03% |
Volcon, Inc. has entered into a Supplier Agreement with Venom-EV, appointing Volcon as Venom’s supply representative for its gold carts. The agreement allows Volcon to purchase up to $3 million worth of products from Venom’s manufacturer, with payment terms set at net 90 days. Venom will handle shipping, tariffs, and product liability, while Volcon will issue shares to Venom based on product purchases, subject to shareholder approval. The agreement, effective February 25, 2025, has a one-year term with possible extensions and includes provisions for termination in case of insolvency or breach. Additionally, Volcon’s Board of Directors approved new committee appointments on February 21, 2025.